Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.64 |
| ▸ | HTR7 | P34969 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2131424 | 0.91 | ABL1 (0.63) | ALDH1A1HTR7SMN1; SMN2KDM4EPOLB | |
| SCHEMBL2131896 | 0.90 | ALDH1A1 (0.60) | ALDH1A1HTR7SMN1; SMN2KDM4EPOLB | |
| SCHEMBL14301937 | 0.88 | HTR7 (0.59) | ALDH1A1HTR7SMN1; SMN2KDM4EPOLB | |
| SCHEMBL2841801 | 0.87 | ALDH1A1 (0.68) | ALDH1A1HTR7SMN1; SMN2KDM4EPOLB | |
| SCHEMBL15224106 | 0.86 | SIGMAR1 (0.69) | ALDH1A1HTR7SMN1; SMN2KDM4EPOLB | |
| SCHEMBL9988381 | 0.86 | HTR7 (0.66) | ALDH1A1HTR7SMN1; SMN2KDM4EPOLB | |
| SCHEMBL9819732 | 0.86 | TSHR (0.71) | ALDH1A1HTR7SMN1; SMN2POLBLMNA | |
| SCHEMBL3920370 | 0.85 | LMNA (0.55) | ALDH1A1HTR7SMN1; SMN2KDM4EPOLB | |
| SCHEMBL10981139 | 0.83 | HTR7 (0.63) | ALDH1A1HTR7SMN1; SMN2KDM4EPOLB | |
| SCHEMBL15224157 | 0.83 | HTR7 (0.63) | ALDH1A1HTR7SMN1; SMN2KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912329-B2 | Composition for treatment of tuberculosis | BioVersys AG (CH) | 2014-12-16 | — | — | US | disclosed |
| US-8912329-B2 | Composition for treatment of tuberculosis | BioVersys AG (CH) | 2014-12-16 | — | — | US | disclosed |
| US-8912329-B2 | Composition for treatment of tuberculosis | BioVersys AG (CH) | 2014-12-16 | — | — | US | disclosed |
| US-20120238750-A1 | AROMATIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-20 | — | — | US | disclosed |
| US-20120238750-A1 | AROMATIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-20 | — | — | US | disclosed |
| US-8236826-B2 | Diarylether derivatives as antitumor agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-8236826-B2 | Diarylether derivatives as antitumor agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-8188277-B2 | Aromatic compounds for suppressing the generation of collagen | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-8188277-B2 | Aromatic compounds for suppressing the generation of collagen | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| EP-2445495-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | Bioversys AG (CH) | 2012-05-02 | — | — | EP | disclosed |
| US-20120101080-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | BioVersys AG (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20120101080-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | BioVersys AG (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20120101080-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | BioVersys AG (CH) | 2012-04-26 | — | — | US | disclosed |
| WO-2010149761-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | BIOVERSYS GMBH (CH) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010149761-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | BIOVERSYS GMBH (CH) | 2010-12-29 | — | — | WO | disclosed |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| WO-2007066784-A2 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101080-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | PRMT7, NCOA3, PRMT3 | ALDH1A1 3428/4885HTR7 127/4885SMN1; SMN2 4154/4885 |
| US-20120238750-A1 | AROMATIC COMPOUND | CBR1, CBR3, CYP1A1 | ALDH1A1 565/4885HTR7 2168/4885SMN1; SMN2 4313/4885 |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | ROS1, CBR1, CBR3 | ALDH1A1 265/4885HTR7 4206/4885SMN1; SMN2 3224/4885 |
| US-20070270422-A1 | Aromatic Compounds | COL1A1, COL2A1, COL14A1 | ALDH1A1 475/4885HTR7 1316/4885SMN1; SMN2 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.